What a cancer 'stage' actually means, and what it does not

A cancer diagnosis usually arrives with a number attached: stage I, stage III, stage IV. It is among the most consequential facts in the whole record, and it is also one of the most misunderstood. Stage is not a measure of how aggressive a cancer looks under a microscope, and it is not a running score that ticks upward as time passes. It is a description, fixed at diagnosis, of how far the cancer has spread — and that single description shapes prognosis and treatment more than almost anything else that is known about the disease.

The TNM system underneath the numbers

Most solid tumours are staged with the TNM system, maintained internationally by the American Joint Committee on Cancer (AJCC), whose staging manual the AJCC describes as the benchmark for classifying patients with cancer, defining prognosis, and determining treatment approaches [s1]. TNM records three separate things: T, the size or local extent of the primary tumour; N, whether and how far it has reached nearby lymph nodes; and M, whether it has metastasised to distant organs [s1]. Each gets its own value — a tumour might be T2 N1 M0 — and the combination is then rolled up into an overall stage group, conventionally written 0 through IV, with stage 0 denoting a pre-invasive lesion that has not yet broken through into surrounding tissue and stage IV denoting distant spread.

Cancer registries often use a simpler three-way summary — localised, regional, or distant — but the underlying idea is the same. What matters is anatomical reach: how much cancer there is, and how far from where it started.

The AJCC has been deliberately widening what the eighth edition of its manual calls a bridge from a population-based to a more personalised approach, folding non-anatomic and molecular factors into staging where the evidence is strong enough, but only where it is strong [s1]. Anatomy remains the spine of the system.

Stage is not grade, and the two are easy to confuse

Grade is a different axis entirely. It describes how abnormal the cancer cells look compared with normal tissue — how disordered, how fast-dividing — and is judged by a pathologist on the biopsy. Stage describes where the cancer is; grade describes what it is like. A small tumour that has not spread can be high-grade, and a low-grade tumour can present at an advanced stage. Both feed into a prognosis, but they answer different questions, and a reader who collapses them into one number will misread the record.

Why the number carries so much weight

Stage matters because prognosis tracks it closely. The clearest illustration is a cancer that is usually caught late. In pancreatic ductal adenocarcinoma, most patients present with locally advanced disease, roughly 30 to 35 percent, or with metastatic disease, roughly 50 to 55 percent, and only about 10 to 15 percent have disease that is resectable at presentation [s2]. Because surgery offers the best chance of long-term control, that stage distribution is a large part of why the cancer is so lethal — the US Preventive Services Task Force notes it is projected to become the second-leading cause of cancer death in the country [s2]. The lesson generalises: for many cancers, the same disease found earlier and found later are nearly different illnesses in terms of what treatment can achieve.

The same logic runs through lung cancer. The Task Force puts the overall five-year survival rate at 20.5 percent, but adds that early-stage lung cancer has a better prognosis and is more amenable to treatment [s3] — the entire rationale for screening high-risk people is to move diagnoses to an earlier stage. Across all cancers, the American Cancer Society projected 2,001,140 new cases and 611,720 deaths in the United States in 2024 [s4]; behind those totals, stage at diagnosis is one of the strongest dividing lines between the two figures.

What stage does not do

Two misreadings are worth naming. First, the stage assigned at diagnosis does not change over the course of the illness. If a stage II cancer later spreads, it is not relabelled stage IV in the way the original diagnosis was recorded; clinicians describe that as recurrence or progression, and use a separate clinical restaging to guide the next decision. The founding stage is a permanent part of the record precisely so that outcomes can be compared consistently. Second, stage is a population-level predictor, not an individual verdict. It describes how groups of similar patients have fared, which is why the AJCC has worked to add molecular detail that sharpens the estimate for a given person [s1]. It cannot tell one patient what will happen to them.

None of this is something a person can read off their own symptoms or scans. Staging is done by clinicians using pathology, imaging and sometimes surgery, and the same anatomical finding can be staged differently across cancer types. Anyone facing a new diagnosis should have the specific meaning of their stage — and what it implies for their options — explained by the team managing their care.

Sources

• [s1] AJCC, The Eighth Edition AJCC Cancer Staging Manual, CA: A Cancer Journal for Clinicians, 2017-01-17
• [s2] Pancreatic Cancer: A Review, JAMA, 2021-09-01
• [s3] Screening for Lung Cancer: USPSTF Recommendation Statement, JAMA, 2021-03-09
• [s4] Cancer statistics, 2024, CA: A Cancer Journal for Clinicians, 2024-01-17